Alterity Therapeutics to Present ATH434 Data at International Congress
Ticker: PRNAF · Form: 6-K · Filed: Sep 23, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-data, neurodegenerative-disease, conference-presentation, drug-development
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) presenting key ATH434 trial data this month at major neurology conference.
AI Summary
Alterity Therapeutics Ltd. announced on September 23, 2024, that it will present data from its Phase 2b clinical trial of ATH434 for Multiple System Atrophy (MSA) at the International Congress of Parkinson's Disease and Movement Disorders. The company will also present data from its Phase 2 study of ATH434 in Parkinson's disease patients. These presentations are scheduled for the month of September 2024.
Why It Matters
The presentations will provide crucial updates on the clinical progress of ATH434, a potential treatment for neurodegenerative diseases like MSA and Parkinson's, impacting future development and investor outlook.
Risk Assessment
Risk Level: medium — Clinical trial data presentations carry inherent risk as results may be positive, negative, or inconclusive, directly impacting the company's valuation and future prospects.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- ATH434 (drug) — Therapeutic candidate
- Multiple System Atrophy (MSA) (disease) — Indication for ATH434
- Parkinson's disease (disease) — Indication for ATH434
- International Congress of Parkinson's Disease and Movement Disorders (event) — Conference for data presentation
- September 2024 (date) — Period of presentations
FAQ
What specific data will be presented regarding the Phase 2b clinical trial of ATH434 for Multiple System Atrophy?
The filing indicates that data from the Phase 2b clinical trial of ATH434 for MSA will be presented, but does not specify the exact nature or results of this data.
When are these presentations scheduled to take place?
The presentations are scheduled for the month of September 2024.
What is the significance of incorporating this 6-K into existing Registration Statements?
Incorporating this 6-K into Registration Statements on Form S-8 and Form F-3 means the information disclosed in this report is now part of those broader filings, potentially related to stock offerings or other securities transactions.
What is the former name of Alterity Therapeutics Ltd. and when did the name change occur?
The former name of Alterity Therapeutics Ltd. was PRANA BIOTECHNOLOGY LTD, and the name change occurred on January 5, 2001.
Where is Alterity Therapeutics Ltd. headquartered?
Alterity Therapeutics Ltd. is headquartered at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 203 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-09-23 08:00:19
Filing Documents
- ea0215352-6k_alterity.htm (6-K) — 13KB
- ea021535201ex99-1_alterity.htm (EX-99.1) — 28KB
- 0001213900-24-080809.txt ( ) — 42KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 23, 2024 2